Drug Profile

GB 401

Alternative Names: GB-401

Latest Information Update: 22 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GrayBug inc.
Developer CalciMedica
Class Antiglaucomas
Mechanism of Action Beta adrenergic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Suspended Open-angle glaucoma

Most Recent Events

20 Mar 2023 GrayBug inc. has merged with CalciMedica to form CalciMedica
11 Aug 2022 Suspended - Preclinical for Open-angle glaucoma in USA due to cost-containment measures (Intravitreous)
30 Mar 2022 Graybug Vision plans a phase I trial for Open-angle glaucoma (Implant) in Q1 of 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com